China Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun Pharma is an integrated pharmaceutical company with interests all along the value chain, from API to finished products, distribution, medical…
China Medical University Healthcare System Many key figures from the pharmaceutical industry have told us that the hospitals in Taiwan are the keystone to the country’s healthcare industry: the hospitals provide a very important service linking the latest innovations from pharmaceutical companies to the people, and helping encourage growth and innovation. I’d like to start…
ChinaBio® LLC This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level, Beijing is usually perceived as better in science, and Shanghai as better in business. That probably isn’t as clear-cut now…
Pfizer China It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers in Shanghai and Wuhan, business operations in over 200 cities and eight state-of-the-art plants in Dalian, Suzhou and Wuxi. Moreover,…
European Union Chamber of Commerce in China The Chamber recently released this year’s European Business in China Business Confidence Survey – what were some of its key takeaways? There are four main points to the Survey. The first has to do with not only China but the rest of the world. China’s growth has been stronger than…
Servier China Servier was one of the first pharmaceutical companies to establish a presence in China back in 1979. How has Servier’s presence evolved alongside China’s huge transformations of the last decades? Indeed, we are very proud to be one of the pioneering foreign companies in China’s pharmaceutical market. The year was…
Servier China In 2012 Servier China became the 3rd largest affiliate within the Servier group. How has the company progressed since then? Servier-China is a linchpin for Servier. Servier-China has become the biggest subsidiary in terms of personnel, with over 1200 people, and today we are number one in the Company in…
Lundbeck China Since this interview, Michael Ryde has left Lundbeck China and is now working as Commercial Counsellor, Teamleader Health, at the Danish Embassy in Beijing. Oscar Parra currently holds the position of General Manager for Lundbeck China. Lundbeck originally sold its products in China exclusively through partners for several years. What…
China Pharmaceutical Enterprises Association First, let me briefly introduce myself. I used to work in Fuxin, a small city in the industrially advanced province of Liaoning which is equivalent to a state in the US. I worked in a company’s pharmaceutical factory for twenty years holding various positions such as technology director, factory head,…
China Association of Traditional Chinese Medi You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely involved with what’s happening in China? I started the operations in China almost 16 years ago, and I started them…
China Pharmaceutical Industry Association (CPIA) You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group. Could you highlight the main evolutions of the Chinese pharmaceutical industry through these fast-changing times? It is indeed true that we have undergone tremendous…
China MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps in the country. You just arrived in China in February. The country managers we’ve met have all been here for…
See our Cookie Privacy Policy Here
